Jump to ContentJump to Main Navigation
Contents

Inhibition of Coagulation and Fibrinolysis

Chapter:
Nomenclature
Author(s):

Harriet S. Meyer

Inhibition of Coagulation and Fibrinolysis

Inhibition of Coagulation.

The following sample terms are included for reference. Expand at first mention in accordance with 14.11, Abbreviations, Clinical, Technical, and Other Common Terms.

Term

Abbreviation

α1-antitrypsin

AAT

α2-macroglobulin

AMG

antithrombin III

ATIII

α-ATIII isoform

α-ATIII

β-ATIII isoform

β-ATIII

ATIII/heparin complex

C1 inhibitor

C1 INH (see also 15.8.3, Immunology, Complement)

heparin cofactor II

lupus coagulation inhibitor (also called lupus anticoagulant)

LCI

protein C

activated protein C

APC

protein S

protein Z

serpin (serine protease inhibitor)

tissue factor pathway inhibitor

TFPI

Note: Protein C was named for an investigator’s chromatographic fraction C in which it was discovered. The S in protein S refers to Seattle, where it was discovered. Protein S is not the same as S protein; see also 15.8.3, Complement.

Fibrinolysis (Fibrin Degradation, Clot Degradation, Thrombolysis).

The following sample terms represent entities that take part in fibrinolysis or its inhibition. Expand at first mention in accordance with 14.11, Abbreviations, Clinical, Technical, and Other Common Terms:

Term

Abbreviation

α2-plasmin inhibitor, α2-antiplasmin

α2PI

aminocaproic acid (amicar)

ACA

ε-ACA

EACA

dimerized plasmin fragment D

D-dimer

fibrin degradation products or fibrin split products

FDP or FSP

Glu-plasminogen (see also “Amino Acids” in 15.6.1, Genetics, Nucleic Acids and Amino Acids)

Lys-plasminogen (see also “Amino Acids” in 15.6.1, Genetics, Nucleic Acids and Amino Acids)

a plasminogen activator inhibitor

PAI-1

protein C inhibitor

PAI-3

thrombin-activated fibrinolytic inhibitor

TAFI

tissue plasminogen activator (when a specific therapeutic formulation of tPA is intended, use the USAN term; see 15.4, Drugs)

tPA

tPA receptor

tPAR

urokinase or urinary plasminogen activator

uPA

uPA receptor

uPAR

Tests of Coagulation.

Two among several tests of coagulation are the prothrombin time (PT) and the partial thromboplastin time (PTT). When the more common activated partial thromboplastin time (aPTT) is used instead of the PTT, this should be specified.

Traditionally, the prothrombin ratio (PTR) had been reported as a ratio of the patient’s PT to the mean laboratory control PT. Reporting the PTR has been refined by use of a modified PTR, the international normalized ratio (INR).14-16 In accordance with a 1985 policy statement of the International Committee for Thrombosis and Hemostasis and the International Committee for Standardization in Hematology,14 authors are encouraged to report the INR if at all possible. Unlike conversions between conventional and SI units (see 18.1, Units of Measure, SI Units), there is no simple conversion factor from the PTR to the INR since the international sensitivity index (ISI) of the thromboplastin used in the actual assay performed must be known. The INR is calculated as shown:

INR = PTRISI

Authors should specify the exact method by which their results were initially reported by the laboratory performing the assay and the method of conversion, if any, used on the original results.

Previous | Next